Log in to search using one of your social media accounts:

 

Is Interim Pet-CT Scan Influencing the Choice of Subsequent Therapy in Hodgkin ’s Lymphoma Patients in Lebanon?
In Hodgkin ’s lymphoma, Pet-CT scan has established itself as the functional imaging modality of choice when it comes to evaluation and guiding treatment decisions. However, it remains an expensive imaging technique and therefore the number of PET CTs is limited for each patient. Recent studies show that Int erim Pet-CT scan is gaining an important role as a predictor of survival and an influencer for treatment modifications. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Fouad Kerbage, Marcel Massoud, Elie Akoury, Layale Rached, Riwa Sakr, Georges Rameh, Fady Nasr, Georges Chahine Source Type: research

PET-CT Adapted Therapy for Advanced Hodgkin Lymphoma: A Systematic Review of the Literature
Hodgkins, PET-CT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Iuliana Vaxman, Irina Amitai, Ronit Gurion, Liat Vidal, Eldad Dann, Pia Raanani, Anat Gafter-Gvili Source Type: research

Therapy Related Myeloid Neoplasia in Hodgkin Lymphoma after Autologous Stem Cell Transplantation (ASCT) – A Case Report
Therapy-related myeloid neoplasms (t-MN) are recognized complications of ASCT in lymphoma patients, and a leading cause of nonrelapse-related mortality (NRM). Several studies have attempted to identify the risk factors associated with t-MN after ASCT in lymphoma patients; however, these studies are limited by their observational design and relatively small number of t-MN patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Aleksandra Pivkova Veljanovska, Borce Georgievski, Martin Ivanovski, Lidija Cevreska, Irina Panovska Stavridis Source Type: research

Lymphoma and Leukemia Burden in Russia 2014: Comparison with Nordic Countries and Possible Cancer Registration Quality Issues
Lymphoma, leukemia, incidence, mortality. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Polina Shilo, Anton Barchuk, IIya Zuzgin, Sergey Alexeev Source Type: research

Secondary Hodgkin Lymphoma and MDS after Paclitaxel-Carboplatin Treatment in a Patient with Small Cell Lung Cancer
The rapid development of new therapies that improve patients ’ quality of life and treat various diseases has led to occurrence of more complex adverse drug reactions. This is obvious in cancer therapy where adverse events are more often neglected by the clinicians because of the primary goal of cancer therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Marija Petrushevska, Irina Panovska Stavrdis, Gordana Petrusevska Source Type: research

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy
The mutational profile of classical Hodgkin Lymphoma (cHL) is poorly characterized, and the genetics and evolution of refractory disease is completely unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Valeria Spina, Alessio Bruscaggin, Martina Di Trani, Maurizio Martini, Silvia Locatelli, Elisa Cupelli, Gabriela Forestieri, Adalgisa Condoluci, Annarosa Cuccaro, Alden Moccia, Anastasios Stathis, Clara Deambrogi, Fary Diop, Georg St üssi, Franco Cavalli Source Type: research

Single Institution Experience with Nivolumab in Treatment of Patients with Relapsed or Refractory Hodgkin ’s Lymphoma
Nivolumab, Hodgkin ’s lymphoma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Barbora Ka šperová, Miriam Ladická, Ľuboš Drgoňa, Radoslav Greksák, Ivona Bizikova, Ladislav Fekete, Martin Rázus, Andrej Vranovský Source Type: research

Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin ’s Lymphoma: The Real World Experience of a Single Bone Marrow Transplant Center in Salvador/Bahia
Brentuximab vedotin (BV) was reported to be effective when used as consolidation after autologous transplantation in patients with high-risk Hodgkin ’s Lymphoma (HL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Laryssa Arag ão, Ohana Bispo, Hugo Carvalho, Alex Silva, Vitor Souza, Lilian Carvalho, Tiago Freitas, Luciene Oliveira, Bruna Salvino, Marco Araujo, Suellen Simoes, Adriana Barretto, Alessandro Almeida, Simone Viana Source Type: research

Hodgkin ’s Disease and Paraproteinaemia
Paraproteinaemia is not normally associated with Hodgkin ’s disease (HD). Only few cases of HD occurring in association with monoclonal immunoglobulins have been described in the literature. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Hunan Julhakyan, Tatyana Moiseeva, Lyubov Al-Radi, Valentina Dvyrnik, Sergey Kravchenko, Alla Kovrigina, Andrey Sudarikov, Valeriy Savchenko Source Type: research

Incidence Patterns for Hodgkin Lymphoma in Armenia: A Population-Based Study
Hodgkin lymphoma (HL) accounts for approximately 10% of all lymphomas and approximately 0.6% of all cancers diagnosed in the developed world annually. In the United States there are around 8000 new cases yearly diagnosed. The disease is reported to be slightly more common in males. The information on incidence patterns of HL in developing countries is limited. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jemma Arakelyan, Diana Andreasyan, Arevik Torosyan, Lilit Sargsyan, Lusine Hakobyan, Samvel Iskanyan, Sergey Mkhitaryan, Ruzanna Papyan, Samvel Bardakchyan, Liana Avetisyan, Armen Tananyan, Gevorg Tamamyan Source Type: research

Autologous Stem Cell Transplant in Refractory Relapsed Hodgkin's Lymphoma: More than 10 years of Institutional Experience
Hodgkin's lymphoma refractory relapse, Autologous transplant. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Lautaro Sardu Source Type: research

Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205)
Hodgkin lymphoma (HL) patients who have relapsed after autologous hematopoietic cell transplantation (HCT) and received nivolumab may achieve adequate disease control and be eligible for allogeneic (allo)-HCT. US Prescribing Information recommends monitoring for allo-HCT complications after nivolumab —eg, hyperacute graft-versus-host disease (GVHD), grade (G) 3–4 GVHD, steroid-requiring febrile syndrome (SRFS), and other immune-mediated reactions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Carmelo Carlo-Stella, Graham P. Collins, Philippe Armand, Pier Luigi Zinzani, Jonathon B. Cohen, Ahmad Halwani, Michael Millenson, Mariano Provencio, Eva Domingo Domenech, Lisa Giulino-Roth, Luca Castagna, Kazunobu Kato, Mihaela Popa McKiver, Anne Sumbul, Source Type: research

Lenalidomide Use as Part of Induction Chemotherapy Does Not Increase the Risk Of Peri-Transplant Venous Thromboembolic Events (VTE) in Patients Who Undergo Autologous Stem Cell Transplant for Multiple Myeloma
Lenalidomide (len) is approved for treatment in Multiple Myeloma (MM) Use of len has been associated with an increase in venous thrombotic events (VTE) and aspirin prophylaxis is recommended for pts who are on active treatment with len. Autologous stem cell transplant (ASCT) is used during the treatment of MM after initial induction therapy. The use of intravenous catheters and hospitalization increase the risk of VTE in peri-transplant period. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Naresh Bumma, Monica Peravali, Ghayathri Jeyakumar, Seongho Kim, Asif Alavi, Divaya Bhutani, Lois Ayash, Voravit Ratanatharathorn, Joseph Uberti, Abhinav Deol Tags: Multiple Myeloma Source Type: research

The Correlation between CD44 and Atypical Monoclonal Proteins in Multiple Myeloma
Multiple Myeloma (MM) is a clonal disorder of plasma cells that originates in the bone marrow. Annual incidence of MM in Armenian population is 4 from 100000 people. Interleukin-6 (IL-6) is the major survival and growth factor for myeloma cells (MC). IL-6 promotes the proliferation of human MC and prevents apoptosis of it. However, IL-6 alone is not sufficient to ensure MC survival. It is dependent on many factors like different adhesion molecules such as the integrin family and CD44. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Aline Aywaz, Smbat Daghbashyan, Hasmik Dadayan, Narine Ghazaryan, Armine Pepanyan Source Type: research

Current Practices in Managing Multiple Myeloma (MM): Elucidating Educational Needs of Hematology/Oncology Clinicians
With the rapidly evolving treatment landscape, clinicians managing patients with MM base clinical judgment on their understanding and translation of clinical data into practice. Gaps in knowledge, competence, or confidence can impede implementation of best practices. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Linda M. Ritter, Sara R. Fagerlie, Irene M. Ghobrial, Ravi Vij, Patricia Repetto Source Type: research

Trial in Progress: Phase I Study of Actinium-225 (225Ac)-Lintuzumab in Patients with Refractory Multiple Myeloma
225Ac-lintuzumab is a radioimmunoconjugate composed of 225Ac (t ½=10 days), which emits 4 α-particles, linked to a humanized anti-CD33 monoclonal antibody. CD33 antigen is expressed on multiple myeloma (MM) plasmocytes in approximately 20% - 35% of MM patients and is a poor prognostic factor. Radioimmunotherapy with a particle-emitting constructs of the anti-C D33 monoclonal antibody lintuzumab has demonstrated safety and antileukemic effects in acute myeloid leukemia. Because it is targeting myeloid hematopoietic cells and malignant plasmocytes expressing CD33, 225Ac-lintuzumab may have less extramedullary to...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Moshe Yair Levy, Dragan Cicic, Greory Bergonio, Mark Berger Source Type: research

CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Antitumor immune responses in multiple myeloma (MM) may be suppressed through overexpression of the programmed death-1 (PD-1) receptor on effector cells and the PD-L1 ligand on myeloma cells (Liu et al, Blood 2007; G örgün et al, Clin Cancer Res 2015). Nivolumab, an anti–PD-1 monoclonal antibody (mAb), blocks PD-1 checkpoint signaling to enhance antitumor responses, and shows modest activity as monotherapy for relapsed/refractory (RR) MM (Lesokhin et al, J Clin Oncol 2016). Elotuzumab, an anti-SLAMF7 mAb, di rectly activates natural killer (NK) cells and mediates antibody-dependent cellular cytotoxicity. (S...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sagar Lonial, Paul Richardson, Donna Reece, Hesham Mohamed, Suresh Shelat, Jes ús San Miguel Source Type: research

Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data
In the Phase 3 ELOQUENT-2 trial, elotuzumab plus lenalidomide and dexamethasone (ELd) showed a 30% reduced risk of progression/death vs lenalidomide/dexamethasone and acceptable safety in patients (pts) with relapsed/refractory multiple myeloma (RRMM). However, therapies for pts refractory or intolerant to lenalidomide are needed. Pomalidomide has shown activity in lenalidomide-refractory pts and enhanced elotuzumab efficacy in a mouse model. Therefore, pomalidomide was combined with elotuzumab and dexamethasone (EPd) in this Phase 2 multicenter single-arm study (NCT02612779). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sundar Jagannath, Jesus Berdeja, Robert Rifkin, Craig Cole, Michael A. Thompson, Rosanna J. Ricafort, Amanda Scofield, Hesham Mohamed, Oumar Sy, Ravi Vij, William Bensinger Source Type: research

Extramedullary Multiple Myeloma: Clinical Features and Prognosis in Argentina
Multiple myeloma is a heterogeneous disease. Up to one-third of patients may present extramedullary disease which is associated with a worse prognosis. Data from Latin America is scarce. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Cristian Seehaus, Natalia Schutz, Erika Brulc, Dorotea Fantl Source Type: research

Increased Semaphorin-4D and Plexin-B1 Levels in Multiple Myeloma Patients May Contribute to Osteolytic Bone Disease
During bone remodeling, semaphorin 4D (Sema4D) binds to its receptor plexin-B1, and the downstream molecular cascade ultimately modulates osteoblast motility. It has been suggested that multiple myeloma (MM) cells may utilize Sema4D to suppress osteoblast activity and bone formation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, Tina Bagratuni, Dimitrios Christoulas, Maria Gavriatopoulou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos Source Type: research

A Revised Staging System for Waldenstr öm's Macroglobulinemia
A significant proportion of patients with Waldenstr öm's Macroglobulinemia (WM) can survive for more than 10 years, but some patients die early during the course of the disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Maria Gavriatopoulou, Efstathios Kastritis, Marie Christine Kyrtsonis, Evdoxia Hatjiharissi, Eirini Katodritou, Panagiotis Repousis, Argiris Symeonidis, Michalis Michael, Anastasia Pouli, Nikolaos Giannakoulas, Dimitrios Christoulas, Aikaterini Megalakaki Source Type: research

Comparison of Peripheral Neuropathy Between the Original and a Generic Bortezomib in Multiple Myeloma Patients
Bortezomib has been the backbone of multiple myeloma treatment for more than 10 years, but its use in Brazil is very limited because of cost and reimbursement issues. The availability of generic bortezomib may increase the access of patients but the safety issues concern Brazilian health care professionals and patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Pedro Ivo Da Silva, Ana Carolina Figueiredo Modesto, Tatyana Xavier Almeida Matteucci Ferreira, Renato Sampaio Tavares, Danielle Le ão Cordeiro de Farias Source Type: research

An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
As the multiple myeloma treatment paradigm moves to focus on extended therapy, new efficacious and tolerable proteasome inhibitor-based combinations are needed to give patients who may not be candidates for immunomodulatory drug-based therapy the flexibility of taking their treatment at home. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Meletios Dimopoulos, Sebastian Grosicki, Wies ław Jędrzejczak, Hareth Nahi, Astrid Gruber, Markus Hansson, Catriona Byrne, Richard Labotka, Zhaoyang Teng, Huyuan Yang, Norbert Grzasko, Shaji Kumar Source Type: research

Relative Progression-Free Survival Over Time with Novel Triplet Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma
In combination with lenalidomide (Revlimid ®, R) and dexamethasone (d), elotuzumab (Empliciti™, E), carfilzomib (Kyprolis®, K), ixazomib (Ninlaro®, N) and daratumumab (Darzalex®, D) have been approved for treatment of relapsed/refractory multiple myeloma (RRMM). In randomized, controlled trials, ERd, KRd, NRd and DRd reduced the risk o f disease progression/death versus Rd. However, there are no known head-to-head trials comparing these regimens. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Keith A. Betts, Clara Chen, Miriam L. Zichlin, Alexander Brun, James E. Signorovitch, Dinara Makenbaeva Source Type: research

The Efficacy and Toxicity Profile of a Novel Panobinostat, Bortezomib and Dexamethasone Regime
Panobinostat, Bortezomib and Dexamethasone showed a PFS advantage compared with Bortezomib and Dexamethasone alone in the PANORAMA1 trial. Initial attempts to use this regimen in our patient group saw significant discontinuation rates due to poor tolerance, in particular grade 3-4 diarrhoea and neuropathy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Randal Stronge, Matt Cross, Kevin Boyd Source Type: research

Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT)
Triplet combinations including a proteasome inhibitor (PI) have been proven superior to doublets in NDMM. The only PI currently approved for use in NDMM is injectable bortezomib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Shaji Kumar, Jesus Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan Kaufman, Deborah Berg, Eileen Liao, Vincent Rajkumar, Paul Richardson Source Type: research

Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT)
Addition of a proteasome inhibitor (PI) to a doublet backbone therapy improves efficacy in NDMM patients. Results of a phase 1/2 study of the oral PI ixazomib given weekly in combination with Rd in NDMM were published previously. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Paul Richardson, Craig Hofmeister, Cara Rosenbaum, Myo Htut, David Vesole, Jesus Berdeja, Michaela Liedtke, Ajai Chari, Stephen Smith, Daniel Lebovic, Noopur Raje, Eileen Liao, Xiaoquan Zhang, Deborah Berg, Rachid Baz Source Type: research

The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685)
Bortezomib-melphalan-prednisone (VMP) is a standard-of-care regimen for elderly NDMM patients. Whereas bortezomib is administered intravenously or subcutaneously, ixazomib is an oral proteasome inhibitor with a safety profile amenable to extended dosing. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jesus San Miguel, Maria Asunci ón Echeveste Gutierrez, Ivan Špicka, María-Victoria Mateos, Kevin Song, Michael Craig, Joan Bladé, Roman Hájek, Christine Chen, Neeraj Gupta, Catriona Byrne, Vickie Lu, Helgi van de Velde, Sagar Lonial Source Type: research

Primary Plasma Cell Leukemia: Epidemiologic and Clinical Profile from Patients Treated in a Brazilian Single Hematology and BMT Center
We report clinical presentation, laboratory features and treatment responses from patients diagnosed and treated in a University Hospital. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Suellen Riccio, Ohana Bispo, Herbert Santos, Hugo Carvalho, Laryssa Arag ão, Tiago Freitas, Luciene Oliveira, Ana Lúzia Schriefer, Juliana Andrade, Carla Vignal, Monica Botura, Alessandro Almeida, Daniela Dourado, Glória Bomfim, Marco Aurélio Salvino, Source Type: research

A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma
Despite recent advances, treatment of relapsed multiple myeloma (MM) remains a challenge. Pre-clinical studies suggest that bcl-2 inhibition can induce MM cell death and may synergize with bortezomib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Derek Galligan, Nina Shah, Jeffrey Wolf, Sandy Wong, Linda Abramovitz, Brenn Donnelly, Rupa Narayan, Gabriel Mannis, Shagun Arora, Amy Marsala, Miguel Cerejo, Thomas Martin Source Type: research

Identification of Amyloid Component in Bone Marrow Biopsy of Patients in the Diagnosis of Multiple Myeloma
Light chain amyloidosis (AL) is a rare and potentially serious disease. Approximately 10% of patients with AL may submit Multiple Myeloma (MM) associated with the diagnosis. Our study aimed to determine the frequency of amyloid deposits in the bone marrow of patients with Multiple Myeloma in a University Hospital. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ohana Passos, Laryssa Arag ão, Suellen Simões, Hugo Carvalho, Tiago Freitas, Luciene Oliveira, Ana Shrieffer, Juliana Andrade, Carla Vignal, Monica Botura, Alessandro Almeida, Daniela Dourado, Maria Arruda, Marco Araujo, Edvan Crusoe Source Type: research

Combination of Immunochemical Study, Multicolor Flow Cytometry and Visualizing Methods in Response Assessment in Multiple Myeloma
Remission assessment in multiple myeloma (MM) after treatment is performed by measurement of monoclonal paraprotein (MP) in serum and urine, detection of persisting extramedullary components by computed tomography (CT). Deep response (absence of minimal residual disease – MRD) could be evaluated by methods with high sensitivity such as multicolor flow cytometry (MFC), allele-specific PCR. Visualizing systems (MRI and PET-CT) are used to assess heterogeneous pathological involvement of bone marrow (BM) and tissue. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Irina Galtseva, Larisa Mendeleeva, Yulia Davidova, Nikolay Kapranov, Larisa Kuzmina, Vera Troitskaya, Maxim Solovyev, Tatyana Gaponova, Galina Yatsyk, Irina Kostina, Salia Maryna, Hunan Julhakyan, Elena Parovichnikova, Valeriy Savchenko Source Type: research

Our Experience of Using Lenalidomide, Bortezomib and Dexamethasone (RVD) Therapy in Patients with Relapsed/Refractory Multiple Myeloma
Several reports showed promising results with the use of lenalidomide in combination with bortezomib and dexemathasone (RVD) in patients with relapsed/refractory disease, and in those with newly diagnosed high-risk disease. Here we present our experience of using RVD regimen in relapsed/refractory multiple myeloma patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Gayane Pogosyan Source Type: research

The Efficacy and Course of Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma
Multiple myeloma (MM) is characterized by monoclonal proliferation of plasma cells. High-dose chemotherapy with autologous stem cells transplantation is the standard of treatment for patients with MM, who achieved remission. The efficiency of hematopoietic stem cell mobilization varies between patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Aleksandra Bogucka-Fedorczuk, Justyna Rybka, Mateusz Sawicki, Magdalena Laszkowska-Lewko, Katarzyna Wicherska-Paw łowska, Iwona Prajs, Kazimierz Kuliczkowski, Tomasz Wróbel Source Type: research

Arginine Deprivation Sustains PD1 Expression via GCN2 to Promote Immune Escape in Multiple Myeloma: A Novel Metabolic and Immune Check-Point
Despite PD-1 inhibitors pembrolizumab and nivolumab are promising agents in hematological malignancies, obejective response in multiple myeloma (MM) is dismal due to the immune-suppressive bone marrow (BM) environment. Our previous work showed that arginine deprivation, due to increased arginase-1 (Arg-1)-positive myeloid-derived-suppressor cells (MDSC), sustains MM progression, but its role in modulating PD1 axis is unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Alessandra Romano, Nunziatina Laura Parrinello, Ugo Orfanelli, Michela Ghizzinardi, Laura Oliva, Matteo Trudu, Piera La Cava, Francesco Di Raimondo, Simone Cenci, Francesca Paradiso, Irene Ingordo, Floriana Cremasco Source Type: research

Hyperviscosity Syndrome: A 30-year Experience in a Reference Center in Mexico City
The hyperviscosity syndrome (HVS) is a rare entity that is associated with hematologic neoplasms, rheumatic diseases and chronic infections. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: F.M. Armillas-Canseco, D. Mart ínez-Baños, C.F. Hernández-Mata, I.A. Gómez-Ruiz, A. Aguayo-González Source Type: research

Full Standard Doses of Lenalidomide in Bortezomib-Refractory Multiple Myeloma Patients Affected by Renal Failure: A Real-Life Experience
Lenalidomide, available as oral compound, is largely used in the management of newly diagnosed, relapsed or refractory MM. Due to its renal route of excretion, it is mandatory to adjust lenalidomide dose in patients with RI, guided by Creatinine Clearance (ClCr), in order to impede a systemic prolonged exposure that could boost myelosuppression. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Claudio Cerchione, Lucio Catalano, Anna Emanuela Pareto, Davide Nappi, Ilaria Peluso, Katia Ferrara, Maria Di Perna, Irene Zacheo, Alessandra Romano, Fabrizio Pane Source Type: research

Bendamustine-Bortezomib-Dexametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience
Bendamustine is a bifunctional alkylating agent, with low toxicity, proved to be effective in relapsed, refractory (rr) and in newly-diagnosed Multiple Myeloma (MM). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Claudio Cerchione, Lucio Catalano, Anna Emanuele Pareto, Santina Basile, Luana Marano, Ilaria Peluso, Luigia Simeone, Orsola Vitagliano, Salvatore Palmieri, Stefano Rocco, Alessandra Romano, Felicetto Ferrara, Fabrizio Pane Source Type: research

Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM)
WT1, peptide, high risk, immunotherapy, immune response. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Guenther Koehne, Sean Devlin, Neha Korde, Sham Mailankody, Landau Heather, Hani Hassoun, Alexander Lesokhin, Nikoletta Lendvai, David Chung, Nicholas Sarlis, Sergio Giralt, Ola Landgren Source Type: research

The Presence of Interstitial Pneumonitis before Azacitidine-Treatment is an Unfavorable Prognostic Factor in MDS Patients
Azacitidine (AZA) prolongs the survival of patietns with myelodysplastic syndromes (MDS) and is widely used for front-line therapy. Although AZA-therapy rarely causes interstitial pneumonitis (IP), there is no sufficient report of AZA-therapy for MDS patients complicated by IP. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Hiroshi Hayakawa, Satoshi Iwata, Kotaro Miyao, Tomohiro Kajiguchi Tags: Myelodysplastic Syndromes Source Type: research

Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)
MDS, sAML, NGS, somatic mutation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Seongseok Yun, Rami Komrokji, Najla Al Ali, Jinming Song, Christine Vaupel, Mohammad Hussaini, Kendra Sweet, Jeffrey Lancet, Jeff Hall, Alan List, Eric Padron, David Sallman Source Type: research

Chronic Myelomonocytic Leukemia, IPSS-R vs CPSS in Argentina
CMML is a clonal disorder sharing features of myelodysplastic syndromes (MD) and myeloproliferative (MP) disorders. CMML Prognostic Scoring System (CPSS) was designed specifically for CMML patients. The Revised International Prognostic Scoring System IPSS-R has been also validated to stratify CMML MD. There is no data comparing this scoring systems in our population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Maria Agustina Perusini, Natalia Schutz, Jorge Arbelbide Source Type: research

Chronic Myelomonocytic Leukemia Outcome in Argentina
CMML is a clonal disorder sharing features of myelodysplastic and myeloproliferative disorders. Data from Latin America is scarce. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Maria Agustina Perusini, Natalia Schutz, Dorotea Fantl, Jorge Arbelbide Source Type: research

Mean Corpuscular Volume Evaluation for Differential Diagnosis of Myelodysplastic Syndrome and Megaloblastic Anemia: A Study of 130 Patients
The causes of macrocytic anemia are vitamin B12 and folate deficiencies (megaloblastic anemia), medications, alcoholism, hypothyroidism, and myelodysplastic syndrome (MDS). MDS and megaloblastic anemia cannot be easily distinguished from a current medical history or general blood tests. In addition, in some hospitals it takes time to examine vitamin B12, folate, WT1 mRNA, and bone marrow to diagnose this disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Akira Yamamoto, Yui Kambara, Tomohiro Urata, Taiga Kuroi, Taro Masunari, Nobuo Sezaki, Toru Kiguchi Source Type: research

Acute Heart Failure Developing During Azacitidine Therapy: A Retrospective Report
Azacitidine is a chemotherapeutic agent used to treat myelodysplastic syndrome (MDS). In our hospital, a relatively large proportion of patients (25%) given azacitidine developed acute heart failure (HF) associated with a high fatality rate (40%), although no prior research has identified acute HF as a major side effect of azacitidine therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Yui Kambara, Yusuke Meguri, Hiroyuki Sugiura, Akira Yamamoto, Tomohiro Urata, Taiga Kuroi, Taro Masunari, Nobuo Sezaki, Toru Kiguchi Source Type: research

A Cross-Sectional Study of Myelodysplastic Syndrome in a Brazilian Population
Myelodysplastic syndrome (MDS) is a hematologic malignancy associated with widely varying clinical presentations, mutation patterns and patient outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Glaciano Ribeiro, Gustavo Santos, Warlenn Silva, Gabriel Diniz, Fabiana Piassi, S érgio Araujo Source Type: research

Childhood Acute Promyelocytic Leukemia: An Unusual Case of Myelodysplastic Syndrome after Successful Treatment in a Single Cancer Center in Brazil
Cancer survivors may develop a second cancer as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) and this has been an emerging problem for acute promyelocytic leukemia (APL) patients in complete remission (CR). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Marcia Schramm, Teresa Fernandez, Roberto Capela, Alexandre Apa, Kelly Monteso, Viviane Lovatel, Jane Dobbin, Maria Luiza Silva Source Type: research

Outcomes and Mutational Analysis of a Prospective Phase II Trial of Azacitidine in Patients with MDS and AML with Early Post-Transplant Relapse
Post-transplant relapse remains a major cause of treatment failure in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Understanding of the biology of relapse and response to azacitidine treatment remains limited. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Janghee Woo, Barry Storer, Bart Scott, H. Joachim Deeg Source Type: research

Novel EZH2 Mutation in a Patient with Second Primary B-Cell Acute Lymphoblastic Leukemia after del5q Myelodysplastic Syndrome
Although isolated deletion of chromosome 5q22-q35 is common in de novo myelodysplastic syndrome (MDS), its transformation to B-cell acute lymphoblastic leukemia (B-ALL) is extremely rare. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sebastian Burgos Canales, Maria L. Fuente, Guillermo Montalban Bravo, Guillermo Garcia-Manero, Maria J. Mela Osorio Source Type: research

The Influence of Cytogenetics on Splenic Response and Survival in Myelofibrosis Patients on JAK Inhibitors
In the era before the advent of JAK inhibitors, cytogenetic information was used to predict overall survival in myelofibrosis (MF) patients. However, its value in predicting clinical response or survival during treatment with JAK inhibitors remains unknown. The purpose of this study is to determine if cytogenetics may have independent effects on therapy response, as measured by splenic reduction, and overall survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Vincent Ma, Philip Boonstra, Kamal Menghrajani, Cecelia Perkins, Krisstina Gowin, Moshe Talpaz Tags: Myeloproliferative Neoplasms Source Type: research